Completed NA INTERVENTIONAL 3-arm NCT03176485

Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors

Pilot Study to Evaluate the Signaling Pathway Modulation Demonstrated by Raf, MEK, and Kinase Inhibitors In Human Skin With or Without Solar Simulated Light

Sponsor: University of Arizona

Conditions Colon Cancer Differentiated Thyroid Cancer HCC Hepatocellular Carcinoma Melanoma Metastatic Cancer Metastatic Colon Cancer Metastatic Melanoma Renal Cell Carcinoma

Interventions Solar Simulator

Updated 6 times since 2017 Last updated: Jan 3, 2019 Started: Oct 17, 2014 Primary completion: Nov 1, 2018 Completion: Nov 1, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Colon Cancer and Differentiated Thyroid Cancer, this trial is completed. The trial is conducted by University of Arizona and has accumulated 6 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Feb 2019 — Jan 2021 [monthly]

Completed NA

Status: Recruiting → Completed
Jul 2018 — Feb 2019 [monthly]

Recruiting NA

▶ Show 1 earlier version

Jul 2017 — Jul 2018 [monthly]

Recruiting NA

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Arizona

Data source: University of Arizona

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tucson, United States